PolyModels Hub Secures £7 Million Series A to Accelerate Global Expansion and Digital Drug Development
PolyModels Hub, the London‑based biotech software company transforming biopharmaceutical process development, has secured significant new financing in a Series A funding round that will accelerate its global expansion and advance its digital platform for drug development. Founded in 2023 by biotech and pharmaceutical veterans, the startup’s flagship product, ModelFlow, combines advanced modeling, simulation and workflow management to help scientists design, test and optimise complex drug manufacturing processes more efficiently, reducing costs and timelines for bringing new medicines to market.
The latest round raised approximately £7 million (around €7.8–€7.9 million) and was led by investors including Molten Ventures and Marathon Venture Capital, both prominent venture capital firms with a track record of backing high‑growth technology startups. Molten Ventures, a London‑listed venture capital firm, has been actively investing across European tech companies and counts a portfolio of enterprise and software successes, while Marathon Venture Capital focuses on early‑stage investments and has backed PolyModels Hub since its seed round.
This Series A follows an earlier £1.1 million seed round the company closed in 2024, also led by Marathon Venture Capital, that supported the initial development of its digital platform designed to “digitise pharmacology” and modernise process development in drug research. The successful seed raise and rapid growth since then set the stage for the larger Series A commitment, reflecting investor confidence in the company’s potential to reshape how biopharma organisations innovate and scale.
According to company leadership, the new funding will be used to expand engineering and product teams, further enhance the ModelFlow platform, and broaden the company’s reach across international pharmaceutical markets. In early deployments, the technology has already been credited with reducing experimental workloads by more than 90 per cent, transforming traditional lab‑heavy workflows into streamlined, digital processes.
PolyModels Hub’s co‑founder and CEO, Antonio Benedetti, said the pharmaceutical industry is in the midst of “a once‑in‑a‑generation digital transformation,” and that the company’s platform has demonstrated “tangible value” to major partners in a relatively short time. The expansion funded through the Series A, he noted, will help the company deliver its solutions to a broader range of organisations seeking to make drug development faster, more predictable and more cost‑effective.
Ben Wilkinson, CEO of Molten Ventures, emphasised the strategic importance of the investment, noting that PolyModels Hub addresses a “real pain point” for pharmaceutical teams by integrating deep domain expertise with advanced technology, allowing organisations to derive value from digital process optimisation in weeks rather than years. Alex Alexakis, Partner at Marathon Venture Capital, echoed this sentiment, highlighting the firm’s continued support for the company as it scales its platform and impact across the pharma sector.
Industry analysts and commentators have noted that digital and BioTech software solutions like those offered by PolyModels Hub are attracting growing interest from investors, as pharmaceutical companies increasingly seek tools that can streamline both research and commercial manufacturing. The company’s success in securing funding is part of a broader trend of investor focus on technologies that combine artificial intelligence, data‑driven modelling and laboratory science to address bottlenecks in drug development.
With this substantial Series A capital injection, PolyModels Hub is positioning itself to expand its footprint beyond the UK and Europe, strengthen collaborations with major pharmaceutical customers, and accelerate its mission to provide a unified digital backbone that underpins the future of drug design, development and production.
